- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06096116
Estudo de fase 3 sobre a eficácia e segurança da antitrombina derivada do plasma humano (Atenativ) em pacientes resistentes à heparina programados para cirurgia cardíaca que necessitam de circulação extracorpórea
Estudo multicêntrico de fase 3, duplo-cego, controlado por placebo sobre a eficácia e segurança da antitrombina derivada do plasma humano (Atenativ) em pacientes resistentes à heparina programados para cirurgia cardíaca que necessitam de circulação extracorpórea
The primary objective of this study is to evaluate the efficacy of two different doses of Atenativ, versus placebo, in restoring and maintaining heparin responsiveness in adult patients undergoing cardiac surgery necessitating cardiopulmonary bypass (CPB)
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 3
Contactos e Locais
Contato de estudo
- Nome: Cristina Solomon, MD
- Número de telefone: +41 79 585 90 42
- E-mail: Cristina.Solomon@octapharma.com
Locais de estudo
-
-
British Columbia
-
New Westminster, British Columbia, Canadá, V3L0A4
- Recrutamento
- Royal Columbian Hospital
-
-
Ontario
-
Kingston, Ontario, Canadá, K7L2V7
- Recrutamento
- Kingston Health Sciences Centre
-
Toronto, Ontario, Canadá, M5G2C4
- Ainda não está recrutando
- Toronto General Hospital
-
-
Quebec
-
Montreal, Quebec, Canadá, H1T1C8
- Recrutamento
- Montreal Heart Institute
-
-
-
-
-
Ljubljana, Eslovênia
- Recrutamento
- University Medical Centre Ljubljana
-
-
-
-
California
-
Stanford, California, Estados Unidos, 94305-5101
- Recrutamento
- Stanford University School of Medicine
-
-
Florida
-
Miami, Florida, Estados Unidos, 33136
- Recrutamento
- University of Miami
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- Recrutamento
- Massachusetts General Hospital
-
-
North Carolina
-
Durham, North Carolina, Estados Unidos, 27710-1000
- Recrutamento
- Duke University Medical Center
-
Winston-Salem, North Carolina, Estados Unidos, 27157
- Recrutamento
- Atrium Health Wake Forest Baptist
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44195
- Recrutamento
- Cleveland Clinic
-
Columbus, Ohio, Estados Unidos, 43214
- Recrutamento
- The Ohio State University
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- Recrutamento
- OU Health University of Oklahoma Medical Center
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75390
- Recrutamento
- University of Texas Southwestern Medical Center
-
-
-
-
-
Reims, França
- Rescindido
- CHU de Reims, Hôpital Robert Debré
-
Rennes, França
- Retirado
- CHU de Rennes
-
-
-
-
-
Kaunas, Lituânia
- Rescindido
- Hospital of Lithuanian university of Health sciences Kauno Klinikos
-
Vilnius, Lituânia
- Recrutamento
- Vilnius University hospital Santaros Klinikos
-
-
-
-
-
Cambridge, Reino Unido
- Recrutamento
- Royal Papworth Hospital
-
Coventry, Reino Unido
- Recrutamento
- University Hospital Coventry and Warwickshire
-
Middlesbrough, Reino Unido
- Recrutamento
- The James Cook University Hospital
-
-
-
-
-
Bucharest, Romênia
- Recrutamento
- Institute for Cardiovascular Diseases C.C. Iliescu
-
-
-
-
-
Kamenitz, Sérvia
- Recrutamento
- Institute of Cardiovascular Diseases Vojvodina
-
-
-
-
-
Brno, Tcheca
- Recrutamento
- Center of Cardiovascular and Transplant Surgery
-
Prague, Tcheca
- Rescindido
- Institute for Clinical and Experimental Medicine
-
-
-
-
-
Innsbruck, Áustria
- Recrutamento
- University Hospital Innsbruck
-
Vienna, Áustria
- Recrutamento
- Vienna General Hospital AKH, Medical University of Vienna
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Planned cardiac surgery with CPB
- Heparin-resistant patients (pre-CPB Hemochron ACT less than 480 s in the measurement taken between 2-5 minutes following intravenous administration of 500 U/kg UFH)
- Patients between 18 and 85 years of age, inclusive
- Freely given written or electronic informed consent
- In female patients of childbearing potential, a pre-existing negative pregnancy test within 14 days prior to surgery
Exclusion Criteria:
-
Receiving, or have received within the timeframes specified, one or more of the following medications prior to the start of surgery:
- vitamin K antagonists (within 3 days)
- direct oral anticoagulants (within 2 days)
- thienopyridines (ticlopidine within 14 days, prasugrel within 7 days, or clopidogrel within 5 days), unless platelet function is satisfactory according to local standard of care assessment
- ticagrelor (within 5 days), unless platelet function is satisfactory according to local standard of care assessment
- glycoprotein IIb/IIIa antagonist (within 24 hours)
-
Pre-existing coagulopathy, a history of bleeding problems, or a laboratory-diagnosed bleeding disorder (e.g., von Willebrand disease, platelet disorder)
-
Renal insufficiency, defined as serum creatinine level >2.0 mg/dL
-
Thrombocytosis, defined as platelet count >400,000 per μL
-
Known hypersensitivity or allergic reaction to antithrombin or any of the excipients in Atenativ, i.e., human albumin, sodium chloride, acetyl tryptophan, caprylic acid
-
History of anaphylactic reaction(s) to blood or blood components
-
Refusal to receive transfusion of blood or blood-derived products
-
Current participation in another interventional clinical trial or previous participation in the current trial
-
Treatment with any IMP within 30 days prior to screening visit
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Low-dose Atenativ
Patients will receive a single bolus of 30 international units (IU)/kg body weight (BW) Atenativ. |
A solvent/detergent and heat-treated antithrombin concentrate derived from human plasma |
|
Experimental: High-dose Atenativ
Patients will receive a single bolus of 60 international units (IU)/kg body weight (BW) Atenativ. |
A solvent/detergent and heat-treated antithrombin concentrate derived from human plasma |
|
Comparador de Placebo: Placebo
Patients will receive a saline bolus dose |
Half of the patients in the placebo group will be randomised to receive a volume of placebo corresponding to the low dose of Atenativ and the other half to receive a volume of placebo corresponding to a high dose of Atenativ |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Restoring heparin responsiveness
Prazo: During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)
|
The percentage of patients in each group in whom no further therapy containing antithrombin (i.e. frozen plasma or other antithrombin concentrates) is needed for restoring pre-CPB heparin responsiveness after administration of Atenativ or placebo, and for maintaining it during CPB |
During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Amounts of further therapy for restoring heparin responsiveness
Prazo: During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)
|
The comparison between the amounts of further therapy containing antithrombin (i.e., FP or antithrombin concentrates) needed for restoring pre-CPB heparin responsiveness, after administration of Atenativ or placebo, and for maintaining it during CPB |
During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)
|
|
Change in activated clotting time (ACT) values
Prazo: Within 5 minutes following intravenous administration of 500 U/kg unfractionated heparin (UFH) and between 2-10 minutes after IMP infusion
|
The comparison between the change in ACT values following infusion of each of the Atenativ doses and placebo |
Within 5 minutes following intravenous administration of 500 U/kg unfractionated heparin (UFH) and between 2-10 minutes after IMP infusion
|
|
Change in antithrombin plasma levels
Prazo: Within 10 minutes before IMP infusion and between 2 and 10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after the start of IMP infusion
|
The comparison between the change in antithrombin plasma levels following infusion of each of the Atenativ doses and placebo |
Within 10 minutes before IMP infusion and between 2 and 10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after the start of IMP infusion
|
|
Change in heparin usage
Prazo: From end of IMP infusion to the end of surgery
|
The comparison between heparin usage following the infusion of each of the Atenativ doses and infusion of placebo |
From end of IMP infusion to the end of surgery
|
|
FP unit use
Prazo: From the start of IMP infusion until 24 hours following IMP infusion, and until discharge or 7 days after surgery, whichever comes first
|
The comparison between the number of units of FP transfused for reasons other than restoring or maintaining heparin responsiveness, both intraoperatively (from the start of Atenativ or placebo infusion until the start of CPB, during CPB, and from the end of CPB until the end of surgery) and postoperatively (from the end of surgery until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first), as well as cumulatively |
From the start of IMP infusion until 24 hours following IMP infusion, and until discharge or 7 days after surgery, whichever comes first
|
|
Amounts of further antithrombin concentrate for maintaining heparin responsiveness
Prazo: From placement of the final suture or staple until 24 hours following IMP infusion, to discharge or 7 days after surgery, whichever comes first
|
The comparison between postoperative use of antithrombin concentrates for reasons other than restoring heparin responsiveness (from the end of surgery until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first) |
From placement of the final suture or staple until 24 hours following IMP infusion, to discharge or 7 days after surgery, whichever comes first
|
|
Transfusion of allogenic blood products
Prazo: From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first
|
The comparison between transfusion of other allogeneic blood products (e.g., red blood cells [RBCs], platelets, cryoprecipitate, whole blood, albumin, other transfusion), both intraoperatively (from the start of Atenativ or placebo infusion until the start of CPB, during CPB, and from the end of CPB until the end of surgery) and postoperatively (from the end of surgery until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first), as well as cumulatively |
From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first
|
|
Administration of coagulation factor concentrates
Prazo: From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first
|
The comparison between administration of coagulation factor concentrates (fibrinogen concentrate, factor XIII concentrate, recombinant activated factor VII, other therapy)", both intraoperatively (from the start of Atenativ or placebo infusion until the start of CPB, during CPB, and from the end of CPB until the end of surgery) and postoperatively (from the end of surgery until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first), as well as cumulatively |
From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first
|
|
Administration of other haemostatic-relevant therapies
Prazo: From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first
|
The comparison between administration of other haemostatic-relevant therapies (i.e., tranexamic acid, aminocaproic acid, protamine, other therapies), both intraoperatively (from the start of Atenativ or placebo infusion until the start of CPB, during CPB, and from the end of CPB until the end of surgery) and postoperatively (from the end of surgery until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first), as well as cumulatively |
From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first
|
|
Postoperative chest tube drainage
Prazo: From the start of IMP infusion to 24 hours after infusion and until discharge or 7 days after surgery, whichever comes first
|
The comparison between postoperative chest tube drainage volume at 24 hours after the start of Atenativ or placebo infusion, and the comparison between total chest tube drainage volume until discharge or 7 days after surgery, whichever comes first |
From the start of IMP infusion to 24 hours after infusion and until discharge or 7 days after surgery, whichever comes first
|
|
Need for reoperation due to bleeding
Prazo: 24 hours after the start of IMP infusion
|
Comparison of the need for reoperation for bleeding, including description of the cause of bleeding (surgical vs. non-surgical) |
24 hours after the start of IMP infusion
|
|
Cell saver volume
Prazo: During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)
|
The comparison between cell saver volume until the end of surgery |
During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)
|
|
Adverse events
Prazo: From the start of IMP infusion until hospital discharge or 7 days after IMP administration, whichever comes first
|
Incidence of adverse events, including all related and non-related, non-serious adverse events |
From the start of IMP infusion until hospital discharge or 7 days after IMP administration, whichever comes first
|
|
Serious adverse events
Prazo: From the start of IMP infusion until 28 days after IMP administration
|
Incidence of serious adverse events |
From the start of IMP infusion until 28 days after IMP administration
|
|
Survival status
Prazo: At hospital discharge or 7 days after IMP administration (whichever comes first) and at 28 days (+ 4 days) after IMP administration
|
Number of patients surviving in all three cohorts |
At hospital discharge or 7 days after IMP administration (whichever comes first) and at 28 days (+ 4 days) after IMP administration
|
|
Red Blood Cell count
Prazo: Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion
|
Standard haematological parameter |
Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion
|
|
White Blood Cell count
Prazo: Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion
|
Standard haematological parameter |
Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion
|
|
Haemoglobin levels
Prazo: Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion
|
Standard haematological parameter |
Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion
|
|
Haematocrit
Prazo: Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after weaning from CPB, at the end of surgery, and at 24 hours after infusion
|
Standard haematological parameter |
Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after weaning from CPB, at the end of surgery, and at 24 hours after infusion
|
|
Platelet count
Prazo: Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after weaning from CPB, at the end of surgery, and at 24 hours after infusion
|
Standard haematological parameter |
Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after weaning from CPB, at the end of surgery, and at 24 hours after infusion
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- ATN-108
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .